In a filing, Trevi Therapeutics Inc revealed its President & CEO GOOD JENNIFER L unloaded Company’s shares for reported $12784.0 on Sep 06 ’24. In the deal valued at $3.03 per share,4,219 shares were sold. As a result of this transaction, GOOD JENNIFER L now holds 213,313 shares worth roughly $0.84 million.
Then, GOOD JENNIFER L sold 1,840 shares, generating $5,587 in total proceeds. Upon selling the shares at $3.04, the President & CEO now owns 213,313 shares.
Before that, GOOD JENNIFER L sold 40,277 shares. Trevi Therapeutics Inc shares valued at $125,310 were divested by the President & CEO at a price of $3.11 per share. As a result of the transaction, GOOD JENNIFER L now holds 213,313 shares, worth roughly $0.84 million.
H.C. Wainwright reiterated its Trevi Therapeutics Inc [TRVI] rating to a Buy in a research note published on December 12, 2024; the price target was $7.50. Raymond James began covering TRVI with “an Outperform” recommendation on August 30, 2024. H.C. Wainwright started covering the stock on August 30, 2024. It rated TRVI as “a Buy”.
Price Performance Review of TRVI
On Tuesday, Trevi Therapeutics Inc [NASDAQ:TRVI] saw its stock fall -2.46% to $3.96. Over the last five days, the stock has lost -2.94%. Trevi Therapeutics Inc shares have fallen nearly -3.88% since the year began. Nevertheless, the stocks have risen 162.25% over the past one year. While a 52-week high of $4.68 was reached on 01/06/25, a 52-week low of $1.65 was recorded on 01/22/25. SMA at 50 days reached $3.78, while 200 days put it at $3.13.
Levels Of Support And Resistance For TRVI Stock
The 24-hour chart illustrates a support level at 3.82, which if violated will result in even more drops to 3.68. On the upside, there is a resistance level at 4.07. A further resistance level may holdings at 4.18. The Relative Strength Index (RSI) on the 14-day chart is 49.64, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.05, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 62.90%. Stochastics %K at 63.86% indicates the stock is a holding.
How much short interest is there in Trevi Therapeutics Inc?
A steep rise in short interest was recorded in Trevi Therapeutics Inc stocks on 2025-01-31, growing by 0.73 million shares to a total of 4.59 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-31 was 3.87 million shares. There was a rise of 15.81%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on June 13, 2024 when Rodman & Renshaw began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
